Cell Therapeutics, Inc. (CTIC) Tuesday announced the initiation of the commercial launch of Pixuvri in the European Union.
While the drug will enter Sweden, Denmark and Finland in September, it will be launched in Austria and Norway in early October and Germany, United Kingdom and the Netherlands in November. CTI plans to expand availability to France, Italy and Spain as well as other European countries in 2013.
Pixuvri was granted conditional marketing authorization by the European Commission in May and is the first medicinal product licensed in the E.U. to treat adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin Lymphoma or NHL. In the E.U., there are around 37,000 new cases of aggressive B-cell NHL every year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.